PFA therapy works differently from traditional cardiac ablation approaches by delivering high energy electrical pulses to targeted areas of cardiac t ...

Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months ...

PFA is a newer Afib ablation modality touted as reducing the risk of damaging nearby collateral structures, compared with ...

A group of researchers shared their hospital protocol in managing women of childbearing age with Rhesus D (RhD) negativity ...

Variations in inflammation may contribute to vaso-occlusive events (VOEs) during the menstrual cycles of women with SCD, per ...

Sudanese Ambassador to India, Mohammed Abdalla Ali Eltom, expressed profound gratitude for the humanitarian aid provided by the Indian government amid the ongoing conflict in Sudan. He highlighted ...

The following is a summary of "Heme-induced lung injury in human precision-cut lung slices: a new model for acute lung injury ...

Novartis Canada is pleased to announce that Fabhalta® (iptacopan capsules) is now available across Canada for adult patients ...

Recent study evaluated hemolysis in patients supported with the Impella 5.5 percutaneous left ventricular assist device in a single-center experience. The research aimed to characterize the hemolytic ...

为探究急性髓系白血病（AML）相关的关键基因及其与溶血的因果关系，研究人员开展了基于加权基因共表达网络分析（WGCNA）和孟德尔随机化（MR）的研究。结果发现了与 AML 溶血相关的基因，如 TLR4 等，这为 AML 的分子生物学研究提供了新方向。

Both biosimilars are approved to treat patients with several rare diseases, including paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) and ...

In July 2024, the FDA approved EPYSQLI as a biosimilar to Soliris to treat patients with PNH to reduce hemolysis, and aHUS to inhibit complement-mediated thrombotic microangiopathy. In November 2024, ...